Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

– TEMBEXA RFP Response Submitted and Under Review with BARDA –

Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer and Mike Andriole, Chief Financial and Business Officer, will participate in a fireside chat at the Cowen and Company 42nd Annual Health Care Conference on Monday, March 7, 2022 at 12:50 p.m. ET.

Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference

CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research

Chimerix Inc's (NASDAQ: CMRX) preclinical data from its CMX521 program will be featured at the International Conference on Antiviral Research (ICAR) in March. In vivo, studies were performed in an animal model used during the development of a different antiviral therapy that obtained.

Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies

DURHAM, N.C., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Tuesday, March 1, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business overview.

Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Chimerix (CMRX) Report Negative Q4 Earnings? What You Should Know

DURHAM, N.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that a peer-reviewed article entitled, “Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and Desmoplastic Small Round Cell Tumor (DSRCT),” has been published in the journal, Clinical Cancer Research. The article can be accessed here. An interim summary of select cohorts from this study was previously presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021.

Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

DURHAM, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect 2022 Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET.

Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference

– Plenary Session Presentation on Saturday, November 20 –

Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Presented at the Society for Neuro-Oncology Annual Meeting

DURHAM, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX),a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix, will participate in a pre-recorded presentation at the Jefferies London Healthcare Conference that will be made available on Thursday, November 18, 2021 at 3:00 a.m. ET.

Chimerix to Present at Jefferies London Healthcare Conference

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at the Society for Neuro-Oncology (SNO) Annual Meeting 2021, which will be held in Boston, MA from November 19-21, 2021.

Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q3 2021 Results - Earnings Call Transcript

Chimerix Inc (NASDAQ: CMRX) has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of brain cancer).  ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist.

Chimerix Shares Brain Cancer Trial Data

– Announced Positive Topline Results from ONC201 in Recurrent H3 K27M-mutant Glioma –

Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update

Analysts Estimate Chimerix (CMRX) to Report a Decline in Earnings: What to Look Out for

DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends their lives, today announced that it will host a live conference call and audio webcast on Thursday, November 4, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide an operational update.

Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021

DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.

Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2021 Results - Earnings Call Transcript

DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Tuesday, August 10, 2021 at 10:55 a.m. ET.

Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference

DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 5, 2021 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide an operational update.

Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing –

Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming oral and poster presentations at the American Society of Clinical Oncology 2021 Annual Meeting, which will be held virtually June 4-8, 2021.

Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting

Chimerix's (CMRX) CEO Mike Sherman on Q1 2021 Results - Earnings Call Transcript

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –

Chimerix Reports First Quarter 2021 Financial Results and Provides Operational Update

Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon

News for Chimerix Stock (CMRX)